** Shares of Clarity Pharmaceuticals CU6.AX fall 4.5% to A$1.815
** The pharma firm said it will now prioritise development of 64/67Cu-SAR -bis-PSMA for diagnostic and therapeutic applications in prostate cancer
** Jefferies cuts price target to A$4.70 from A$7, retains "buy" rating, based on net present value of co's late-stage pipeline
** Brokerage says it now assumes capital raise in FY26 to address cash reserves and R&D spend to decrease in FY25E
** Also revises Bis-PSMA PCa therapy take-up rate for prostate cancer rate to 5% from 9%
** Clarity stock up 57.1%, YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。